Your cart is emptyContinue Shopping
The treatment option for SMA is currently only available in the US, where Novartis developed a medicine named Zolgensma. The cost of treatment successfully tested by the US Medicines Agency is 2.1 million USD. We will do our best to make Annabel the first infant in Estonia to fight this serious muscle disease. Treatment is needed as soon as possible!
The cost of medicine successfully tested by the US Medicines Agency is 2.1 million USD.
Swedbank AS, Liivalaia 8, 15040, Tallinn, Estonia
For more information on Annabel's condition and donation options, please visit www.helpannabel.eu